Wai Yuen Tong Medicine Holdings Limited reported that on 25 March 2026 it repurchased 3.00 million ordinary shares on the Hong Kong Stock Exchange at HK$0.36 each, involving a cash outlay of HK$1.08 million. The transaction represents 0.267 % of the company’s issued share capital of 1,125.10 million shares.

Including the 3.00 million shares repurchased a day earlier at HK$0.355 per share (HK$1.07 million), the company now holds 6.00 million shares pending cancellation, equivalent to 0.53 % of its issued share base. Aggregate consideration for the two-day buyback stands at HK$2.15 million.

All repurchases were made under the general mandate approved on 19 August 2025, which authorises the company to buy back up to 112.51 million shares. Following the latest transactions, 5.33 % of the mandate has been utilised.

As at 25 March 2026, Wai Yuen Tong’s issued share capital remains unchanged at 1,125.10 million shares with no treasury shares on hand. In line with Hong Kong listing rules, the company is subject to a moratorium on issuing new shares or transferring any treasury shares until 23 April 2026.